Form 4: Lisata Therapeutics CEO David Mazzo Reports Stock Transactions
SEC Form 4 Filing
David Mazzo, CEO of Lisata Therapeutics, reports acquisition of restricted stock and stock options, as well as shares withheld for tax liabilities.
Summary
- David J. Mazzo, the President & CEO of Lisata Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
- On January 9, 2025, Mazzo acquired 81,000 shares of common stock as restricted stock awards.
- These awards vest in four equal installments, with the first vesting on the grant date and subsequent installments vesting annually.
- Also on January 9, 2025, Mazzo acquired 40,000 stock options with an exercise price of $3.8, vesting similarly to the restricted stock.
- Mazzo also had shares withheld to cover tax liabilities related to the vesting of restricted stock on January 9 and 10, 2025.
- Following these transactions, Mazzo directly owns 264,690 shares of common stock, including unvested restricted stock.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports stock transactions by an insider, which is a routine event. The grants themselves are a positive sign of aligning management with shareholder interests, but the tax withholdings are a neutral event.
Positives
- The grant of restricted stock and stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule of the awards incentivizes long-term performance.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
Form 4 filings are standard practice for corporate insiders and provide transparency into their transactions in company stock. This filing indicates ongoing equity-based compensation for the CEO.
Stakeholder Impact
- The transactions may have a minor positive impact on shareholder sentiment as they demonstrate the CEO's continued investment in the company.
- Employees may view the equity grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/09/2025 | Date of restricted stock award grant (81,000 shares), stock option grant (40,000 options), and shares withheld for tax liability. |
| 01/10/2025 | Date of shares withheld for tax liability. |
| 01/09/2035 | Expiration date of stock options. |
| 01/13/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.